title: Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
abstract: The sentinel or tumor-draining lymph node (tdLN) serves as a metastatic niche for many solid tumors and is altered via tumor-derived factors that support tumor progression and metastasis. tdLNs are often removed surgically, and therapeutic vaccines against tumor antigens are typically administered systemically or in non-tumor-associated sites. Although the tdLN is immune-suppressed, it is also antigen experienced through drainage of tumor-associated antigens (TAA), so we asked whether therapeutic vaccines targeting the tdLN would be more or less effective than those targeting the non-tdLN. Using LN-targeting nanoparticle (NP)-conjugate vaccines consisting of TAA-NP and CpG-NP, we compared delivery to the tdLN versus non-tdLN in two different cancer models, E.G7-OVA lymphoma (expressing the nonendogenous TAA ovalbumin) and B16-F10 melanoma. Surprisingly, despite the immune-suppressed state of the tdLN, tdLN-targeting vaccination induced substantially stronger cytotoxic CD8+ T-cell responses, both locally and systemically, than non-tdLN-targeting vaccination, leading to enhanced tumor regression and host survival. This improved tumor regression correlated with a shift in the tumor-infiltrating leukocyte repertoire toward a less suppressive and more immunogenic balance. Nanoparticle coupling of adjuvant and antigen was required for effective tdLN targeting, as nanoparticle coupling dramatically increased the delivery of antigen and adjuvant to LN-resident antigen-presenting cells, thereby increasing therapeutic efficacy. This work highlights the tdLN as a target for cancer immunotherapy and shows how its antigen-experienced but immune-suppressed state can be reprogrammed with a targeted vaccine yielding antitumor immunity.
authors.affiliation: Authors' Affiliations: Ludwig Center for Cancer Research, Université de Lausanne (UNIL), Lausanne, Switzerland.
authors.forename: Laura
authors.initials: L
authors.lastname: Jeanbart
authors.forename: Marie
authors.initials: M
authors.lastname: Ballester
authors.forename: Alexandre
authors.initials: A
authors.lastname: de Titta
authors.forename: Patricia
authors.initials: P
authors.lastname: Corthésy
authors.forename: Pedro
authors.initials: P
authors.lastname: Romero
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Hubbell
authors.forename: Melody A
authors.initials: MA
authors.lastname: Swartz
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D008198:Lymph Nodes / Q000276:immunology* / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000473:pathology; D008546:Melanoma, Experimental; D051379:Mice; D022423:Myeloid Cells / Q000276:immunology / Q000473:pathology; D053758:Nanoparticles; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000276:immunology; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D047368:Tumor Burden
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C516146:CpG ODN-OVA; D009838:Oligodeoxyribonucleotides; D010047:Ovalbumin